Evidence map›Paper›PMID 41105753›Full record

ArticleScience immunology2025

Simultaneous priming of HIV broadly neutralizing antibody precursors to multiple epitopes by germline-targeting mRNA-LNP immunogens in mouse models.

Zhenfei Xie, Xuesong Wang, Yu Yan, Jon M Steichen, Krystal M Ma, Christopher A Cottrell, Eleonora Melzi, Maria Bottermann, Paula Maldonado Villavicencio, Kimmo Rantalainen and 15 more

Abstract read
In one paragraph

Article in Science immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. How Vaccinating People Living With HIV May Guide bNAb‑Based Vaccines.Journal of the International AIDS Society · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Frontiers in immunology · 2026
    Review
  10. Antibody feedback establishes an affinity brake in the germinal center.bioRxiv : the preprint server for biology · 2025
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Zhenfei XieBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0006-9341-4721
Xuesong WangBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0003-8996-1501
Yu YanBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-2756-4899
Jon M SteichenDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-4586-3251
Krystal M MaDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-6519-2531
Christopher A CottrellDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3364-3083
Eleonora MelziBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-1520-735X
Maria BottermannBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-8178-100X
Paula Maldonado VillavicencioBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0008-2321-9669
Kimmo RantalainenDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-3158-9183
Torben SchiffnerDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
John E WarnerBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0001-1043-1643
Stephanie R WeldonBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0001-5384-9946
Thavaleak PrumBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0004-6973-5053
Jordan R Ellis-PughBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0000-4155-3566
Jonathan L TorresDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-0137-8497
Abigail M JacksonDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-9749-9431
Claudia T FlynnInternational AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0003-3067-6781
Gabriel OzorowskiCenter for HIV/AIDS Vaccine Development, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-9695-8138
Sunny HimansuModerna Inc., Cambridge, MA 02142, USA.ORCID 0000-0002-7954-9674
Andrea CarfiModerna Inc., Cambridge, MA 02142, USA.
Andrew B WardCenter for HIV/AIDS Vaccine Development, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7153-3769
Usha NairBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-1927-6889
William R SchiefDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-1120-0150
Facundo D BatistaBatista Lab, Ragon Institute of Mass General, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-1130-9463

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
Design and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIVR01AI147826 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SCHIFFNER, TORBEN · 2019 to 2025
$8.0M
Gates Foundation INV-007522Gates Foundation INV-008813Gates Foundation INV-009585Gates Foundation INV-046626NIAID NIH HHS R01 AI147826NIAID NIH HHS UM1 AI144462
6 · The paper itself

Abstract

Germline-targeting is a promising approach to HIV vaccine development that begins with the elicitation of precursors to broadly neutralizing antibodies (bnAbs), but it remains unclear whether simultaneous elicitation of precursors to multiple epitopes on the HIV envelope (Env) would be inhibited by competition. This study used preclinical mouse models with physiologically relevant frequencies of bnAb precursor-bearing B cells to compare precursor elicitation by coadministration of multiple protein or mRNA lipid nanoparticle (mRNA-LNP) germline-targeting immunogens. These immunogens activate multiple bnAb precursor classes targeting distinct epitopes on Env but with evidence of potential competition. Simultaneous delivery of immunogens encoded by mRNA-LNPs, however, drove maturation across different precursor frequencies and immunogen doses. Furthermore, administration of a cocktail of mRNA-LNP immunogens (N332-GT5 gp151, ApexGT5 gp151, eOD-GT8 60mer, and 10E8-GT12 24mer) led to balanced activation of four distinct bnAb precursor classes, indicating that multiepitope HIV bnAb precursor priming might be successfully implemented in humans but might be immunogen dependent.

Indexed as

AIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesHIV-1HIV AntibodiesHIV InfectionsNanoparticlesRNA, MessengerAnimalsDisease Models, Animalenv Gene Products, Human Immunodeficiency VirusFemaleHumansLiposomesMiceAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing Antibodiesenv Gene Products, Human Immunodeficiency VirusEpitopesHIV AntibodiesLipid NanoparticlesLiposomesRNA, Messenger

Identifiers

PMID41105753
PMCPMC12784461

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.